Displaying drugs 2851 - 2875 of 4298 in total
Acetorphine
Experimental
Illicit
RG-7795
Investigational
TAK-733
TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.
Investigational
MK-7622
MK-7622 has been used in trials studying the treatment of Alzheimer's Disease.
Investigational
MIV-711
Investigational
TAK-715
TAK-715 is under investigation in clinical trial NCT00760864 (Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis).
Investigational
SRA-737
Investigational
ALT-P7
Investigational
F6-734
F6-734 is a bispecific monoclonal antibody with affinity for anticarcinoembryonic antigen (CEA) and anti-diethylenetriamine pentaacetic acid (DTPA) (hMN-14 × m734).[A255217,A255222]
Investigational
INZ-701
INZ-701 is an enzyme replacement therapy under development with the intention to be used for the treatment of calcification disorders of the circulatory system, bones, and kidneys.
Investigational
TAK-754
TAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.
Investigational
JBI-778
Investigational
DMP-777
DMP-777 is a selective inhibitor of polymorphonuclear leukocyte (PMN) elastase.
Investigational
SMART101
SMART101 is an investigational cell therapy comprising human allogeneic CD34-CD7+ T cell progenitors that were cultured ex vivo.
Investigational
MIP-1095 I-123
123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).
Investigational
ANG1005
Investigational
CT103A
CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
Investigational
Naringenin
Experimental
HY10275
HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. HY10275 was rationally designed to...
Investigational
CMLVAX100
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Investigational
Sugemalimab
Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals and being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma.[L32868, L32873] It has been granted the Breakthrough Therapy Designation by the FDA to treat R/R ENKTL...
Investigational
Iron polymaltose
Experimental
Matched Products: … FERLOS 20 MG/ML ORAL ÇÖZELTİ, 10 ADET ... VEGAFERON 100 MG/5 ML ORAL ÇÖZELTİ, 10 ADET ... FERTAMİR 40 MG EFERVESAN GRANÜL İÇEREN SAŞE, 10 SAŞE …
(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
Experimental
Matched Iupac: … (2R,6S,7R)-7-(4-hydroxyphenyl)-10-(methoxymethyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(9),10,12-trien …
Displaying drugs 2851 - 2875 of 4298 in total